› $150,000,000 verdict in personal injury case
The new chewable heartburn medication Metozolv, an orally disintegrating version of Reglan (metoclopramide), has added a warning to its label alerting users of a risk of the serious movement disorder Tardive Dyskinesia with long-term use of the drug. The change to the drug’s safety label was approved by the Food and Drug Administration (FDA) and announced this month.
An estimated 250,000 to 400,000 people in the United States have Tardive Dyskinesia, a disfiguring and debilitating involuntary movement disorder involving symptoms such as lip smacking, tongue thrusting and protruding, eye blinking and bulging, head jerking, facial grimacing, and puckering and pulsing of the lips. The muscle spasms can become painful and embarrassing and often are permanent. But what is most disturbing is that in many cases, the condition could have been prevented.
